Full Press Release Details
Verify to continue
To continue, please confirm that you're a human (and not a spambot).
Checking if the site connection is secure
vimeo.com needs to review the security of your connection before
proceeding.
KURA Neutral Sentiment
Dr. Erba discusses the KOMET-001 Phase 1b safety and tolerability data of ziftomenib, a menin inhibitor, for patients with R/R NPM1-m AML
Key Takeaway: Dr. Erba provided insights on the KOMET-001 Phase 1b trial, focusing on the safety and tolerability of ziftomenib, a menin inhibitor, for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia (AML). The discussion highlights the importance of ongoing clinical trials in assessing new treatment options for this patient population.
Price reaction · baseline $13.23 (2023-12-20T16:25:00.000Z) · hit during market hours · 1 other KURA headline(s) in the window, move may be shared
day 0 close · peak
-6.7%
day 1
-5%
day 3
+5.9%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+116%
120-day peak, hindsight
Typical move
5.7%
average across 9 past catalysts
Cash runway
~25 mo
Low dilution risk
Lead asset
Tipifarnib
Phase 2 · Leukemia, Myelomonocytic, Chronic